Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

Inclusion Criteria: * Males or females between 18 and 50 years, inclusive. * Good general health as determined by means of the screening procedure. * Available for the duration of the trial (68 weeks). * Willingness to participate in the study as evidenced by signing the informed consent document. * Able to understand and comply with planned study procedures. Exclusion Criteria: * Pregnancy as determined by a positive urine human choriogonadotropin (hCG) test (if female). * Participant unwilling to use reliable contraception up until one month following the third immunization (if female and not surgically sterile, abstinent, at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile). * Currently lactating and breast-feeding (if female). * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies. A history of essential hypertension that is well controlled by medication will not be considered exclusionary. * Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits/procedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide). * Known or suspected immunodeficiency. * Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater th…